No clue . It's my understanding that the company use to be full reporting . Had a CFO but deciding the cost ($120,000 a year) was better being put back in product. If they can execute the production of the medical device and generate revenues from that on top of the CBD OIL SALES and edibles and the new kanna sales, the stock will take care of itself.
News 
Market Data 
Discover 
AI
